Bloomberg News

Tigenix to Get 4.95 Million-Euro Loan for Crohn’s Fistula Study

October 03, 2011

Oct. 3 (Bloomberg) -- TiGenix NV’s Cellerix unit will get a 4.95 million-euro loan from the “Madrid Network” to finance the company’s phase III study for complex perianal fistulas in Crohn’s disease patients, TiGenix said today in an e-mailed statement.

To contact the editor responsible for this story: Andrew Clapham at aclapham@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus